In RCC, tumor cells acquire immune surface proteins such as CD14, CD16, CD56 and CD45 from infiltrating lymphocytes and monocytes, that promotes tumor survival by impairing immune effector function (Marcarian et al., 2025). Here, CD14 is linked to neoplasm.